Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <i>BRAF</i> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <i>BRAF</i> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

<b> </b>Dabrafenib plus trametinib combination is approved in Europe for <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to assess efficacy and safety of this combination in a real-world setting. This retrospective multi...

Full description

Bibliographic Details
Main Authors: Jean-Bernard Auliac, Sophie Bayle, Pascal Do, Gwenaëlle Le Garff, Magali Roa, Lionel Falchero, Eric Huchot, Gilles Quéré, Gaëlle Jeannin, Anne-Cécile Métivier, Joëlle Hobeika, Florian Guisier, Christos Chouaid
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
BRAF mutations
dabrafenib
non-small-cell lung cancer
oncogenic driver
targeted therapy
trametinib
Online Access:https://www.mdpi.com/2072-6694/12/12/3608

Internet

https://www.mdpi.com/2072-6694/12/12/3608

Similar Items